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Abstract
Primary ciliary dyskinesia (PCD) is a genetically heterogeneous disorder of motile cilia. Most of
the disease-causing mutations identified to date involve the heavy (DNAH5) or intermediate
(DNAI1) chain dynein genes in ciliary outer dynein arms, although a few mutations have been
noted in other genes. Clinical molecular genetic testing for PCD is available for the most common
mutations. The respiratory manifestations of PCD (chronic bronchitis leading to bronchiectasis,
chronic rhino-sinusitis and chronic otitis media) reflect impaired mucociliary clearance owing to
defective axonemal structure. Ciliary ultrastructural analysis in most patients (>80%) reveals
defective dynein arms, although defects in other axonemal components have also been observed.
Approximately 50% of PCD patients have laterality defects (including situs inversus totalis and,
less commonly, heterotaxy and congenital heart disease), reflecting dysfunction of embryological
nodal cilia. Male infertility is common and reflects defects in sperm tail axonemes. Most PCD
patients have a history of neonatal respiratory distress, suggesting that motile cilia play a role in
fluid clearance during the transition from a fetal to neonatal lung. Ciliopathies involving sensory
cilia, including autosomal dominant or recessive polycystic kidney disease, Bardet-Biedl
syndrome, and Alstrom syndrome, may have chronic respiratory symptoms and even
bronchiectasis suggesting clinical overlap with PCD.
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Primary ciliary dyskinesia (PCD) (MIM#244400) is a genetically heterogeneous, typically
autosomal recessive, disorder characterized by ciliary dysfunction and impaired mucociliary
clearance, resulting in an array of clinical manifestations, including chronic bronchitis
leading to bronchiectasis, chronic rhino-sinusitis, chronic otitis media, situs inversus (in
approximately 50% of cases), and male infertility. The incidence of PCD is estimated at
1/16,000 births, based on prevalence of situs inversus and bronchiectasis.1,2 However, few
PCD patients carry a well-established diagnosis, which reflects, the limited ability to
diagnose this disorder.
The first cases, reported in the early 1900's, and characterized by a triad of symptoms that
included chronic sinusitis, bronchiectasis and situs inversus,3 became known as Kartagener
syndrome. Subsequently, patients with Kartagener syndrome, as well as other patients with
chronic sinusitis and bronchiectasis, were noted to have “immotile” cilia and defects in the
ultrastructural organization of cilia.4-6 Initially, the term “immotile cilia syndrome” was
used to describe this disorder; however, later studies showed that most cilia were motile, but
exhibited a stiff, uncoordinated and/or ineffective beat. The name was changed to “primary
ciliary dyskinesia” to more appropriately describe its heterogeneous genetic base and the
ciliary dysfunction, as well as to distinguish it from the secondary ciliary defects acquired
following multiple causes of epithelial injury.
The “gold-standard” diagnostic test for PCD has been electron microscopic ultrastructural
analysis of respiratory cilia obtained by nasal scrape or bronchial brush biopsy. Recent
studies have identified mutations in several genes encoding structural and/or functional
proteins in cilia. Limited clinical genetic testing is currently available, but a multi-center,
international collaboration is focused on defining additional PCD-specific gene mutations in
order to expand PCD genetic testing. Recently, nasal nitric oxide (NO) measurement has
been used as a screening test for PCD, because nasal NO is extremely low (10-20% of
normal) in PCD patients.7-10 As an adjunct test, nasal NO measurement can identify
individuals with probable PCD (even if ciliary ultrastructure appears normal) to target for
genetic testing. We anticipate that genetic testing for PCD will soon become the “gold
standard” diagnostic test in a growing number of cases.
In summary, we are in the midst of a revolution for the diagnosis, and understanding of
genotype/phenotype correlations in PCD. This effort has greatly benefited from an NIH-
sponsored Rare Disease Network (url: http://rarediseasesnetwork.epi.usf.edu/), and a
consortium focused on studying genetic disorders of mucociliary clearance, including PCD
(url: http://rarediseasesnetwork.epi.usf.edu/gdmcc/index.htm).
CILIARY STRUCTURE AND FUNCTION
Normal ultrastructure of motile cilia
Cilia and flagella are evolutionarily ancient organelles whose structure and function have
been rigidly conserved across the phylogenetic spectrum. Historically recognized for their
role in cell motility and transport of fluids over mucosal surfaces, cilia have recently been
recognized to have a sensory function that modulates elements of development and cell
function. Both motile and sensory cilia are composed of highly organized arrays of
microtubules and attendant accessory elements and their classification is depicted in Fig. 1.
Microtubules are formed from α- and β- monomers of tubulin configured into helical
patterns of protofilaments. The peripheral microtubules in the canonical 9+2 microtubular
pattern of motile cilia are studded with dynein arms that contain ATPases and act as
molecular motors to effect the sliding of the peripheral microtubular pairs relative to one
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another. The outer dynein arms (ODA) are positioned proximal to the ciliary membrane and
the inner dynein arms (IDA) proximal to the central apparatus of the A microtubule. The
dynein arms are large protein complexes each comprised of several heavy, light, and
intermediate chains as shown in Fig. 2. In Chlamydomonas, and likely other eukaryotic cilia
and flagella-bearing cells, the IDA and ODA are spaced in specific linear repeats of 96 nm
and 24 nm, respectively11,12 along the axis of each microtubular pair, where they undergo an
attachment, retraction, and release cycle with the neighboring microtubular pair that imposes
a sliding motility of the pairs relative to one another. The A microtubule in cross-section is
comprised of thirteen protofilaments and shares three protofilaments with the B microtubule.
Studies of isolated axonemes depleted of accessory structures have shown that in the
presence of ATP the microtubular pairs slide upon one another to visible light extinction. It
is thought that some of the accessory structures, including the nexin links, radial spokes, and
ciliary membrane provide shear forces that transition the sliding event to the bending
characteristic of ciliary waveform. In contrast to the 9+2 pattern of motile cilia with dynein
motors, there are structural variants without dynein motors that have a 9+0 microtubular
pattern,13 which are called “primary” cilia. Unlike the numerous motile cilia present on
airway epithelial cells, these primary cilia are borne as solitary appendages. Historically
thought to be non-functional or vestigial, they have been rediscovered in recent years as
structures central to organ positioning during embryologic development and to the detection
of mechanical and chemical gradients. Thus, primary cilia are now recognized as structures
modulating detection, orientation, and positioning. Virtually all cells are capable of
producing a single primary cilium, which lacks dynein arms and is immotile. However, it
has been suggested that populations of both non-motile primary cilia and specialized motile
cilia are present in nodal cells, and that dyneins on the motile populations confer a whirling
motility to the organelle that is distinct from the waveform motility typical of 9+2 motile
cilia. Thus, there are three basic groups of cilia; motile 9+2 cilia with attendant dynein arm
structures (e.g. respiratory epithelial cells), non-motile 9+0 primary cilia lacking dynein
arms (e.g. kidney tubules), and motile 9+0 primary cilia possessing dynein arms (e.g.
embryonic node). In addition to the highly specialized organization of the core of the cilium,
the ciliary membrane exhibits a specialized structure, the ciliary necklace at the base of the
axonemal shaft.14 The ciliary necklace has been speculated to be a docking/assembly site for
axonemal elements, since nascent organizing structures of these arrays have been reported
on the luminal membranes of cells in early stages of ciliogenesis.15
Normal ciliary beat frequency
Two distinctive types of motility are representative of 9+2 and 9+0 motile cilia. Ciliated
epithelial cells bear approximately 200 motile (9+2) cilia that move with both intracellular
and intercellular synchrony. The pattern of beat in 9+2 motile cilia occurs in a waveform
having a forward effective stroke followed by a return stroke. The direction of stroke is a
function of the directional orientation of the central microtubules. In addition to moving in
synchrony, individual cilia in normal cells are very plastic and move fluidly, sometimes
deforming briefly upon encountering resistance and/or particles being transported over the
mucosal surface. Cilia are embedded in a watery periciliary fluid of low viscosity, which
facilitates the rapid beat cycle to move the more viscous overlying layer of mucus. Ciliary
beat frequency ranges from approximately 8-20 Hz under normal conditions, but may be
accelerated by exposure to irritants such as tobacco smoke.16 The mechanism whereby beat
frequency is accelerated has been suggested to be regulated through the activity of nitric
oxide synthases localized in the apical cytoplasm. While baseline ciliary beat frequency is
not thought to be under NO regulation, NO accelerates ciliary beat frequency in response to
challenge through soluble adenylyl or guanylyl cyclase to form their respective cyclic
nucleotides with activation of protein kinase G (PKG) and A (PKA) to accelerate beat
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frequency.17,18 Increases in intracellular calcium fluxes19,20 may also play a role in
accelerating ciliary beat frequency.
In contrast to the forward/return waveform of 9+2 cilia, motile nodal 9+0 cilia beat with a
vertical motion. This type of motility is thought to direct nodal flow “leftward” across the
node, which is necessary for establishment of proper left/right asymmetry.
Cilia composition and conservation across species
The ciliary genome is highly conserved across the phylogenetic spectrum from simple
unicellular eukaryotes and lower animals to functionally complex mammalian cells and
tissues. The genomes for many of organisms are already characterized and the simple
organisms are easily grown in the substantive quantities and manipulated in the laboratory
setting to facilitate structural, functional, and genetic studies. This provides opportunities to
identify cilia-specific mutations that may represent candidate genes for human
ciliopathies.21 Indeed, mutations conferring outer dynein arm defects in primary ciliary
dyskinesia have orthologs in Chlamydomonas.22 Moreover, genes encoding polycystins and
intraflagellar transport proteins in Chlamydomonas also have orthologs with relevance to
polycystic kidney disease.23,24 Hence studying orthologous genes across the various species
is valuable in order to decipher the candidate genes for human ciliopathies.
GENETICS
Genetic heterogeneity; challenges and methods to identify disease-causing genes
Dysfunction of the axonemal structure has been linked to the emerging class of disorders
collectively known as “ciliopathies” which includes PCD / Kartagener syndrome, Bardet-
Biedl syndrome, hydrocephalus, polycystic kidney disease, polycystic liver disease,
nephronophthisis, Meckel-Gruber syndrome, Joubert syndrome, Alstrom syndrome, Jeune
syndrome, and laterality defects.25-28 PCD was the first human disorder linked to the
dysfunction of motile cilia and that will be discussed in detail in this chapter.
Axonemal structure, which is conserved through evolution, is complex and comprised of
multiple proteins; hence, it is not surprising that PCD is a genetically heterogeneous disorder
posing challenges for defining causative genes. Conventional family based genome wide
linkage studies have failed to identify PCD causing genes,29 because combining data from
multiple families limits power when dealing with a genetically heterogeneous disorder, such
as PCD. Multiple other methodologies alone, or in combination, have been successfully
applied to elucidate the genetic basis of PCD, including functional candidate gene
testing,30-34 homozygosity mapping35-37 followed by positional candidate gene analysis,
and comparative computational analysis involving comparative genomics, transcriptomics
and proteomics.38-43 Thus far, mutations have been identified in eight genes (Table 1) in
PCD (DNAI1, DNAH5, DNAH11, DNAI2, KTU, RSPH9, RSPH4A and TXNDC3) but no
genotype/phenotype associations have been defined and these genes are discussed in detail
below:
DNAI1—DNAI1 (dynein axonemal intermediate chain 1) (MIM#604366), was the first
PCD-causing gene to be identified based on the candidate gene approach. This approach
takes advantage of the fact that the axoneme is highly conserved through evolution, and
human orthologs of the genes known to cause specific ultrastructural and functional defect
in other species are candidates for PCD. Chlamydomonas is a bi-flagellate, unicellular algae
with well studied genetics and multiple motility mutants. One such mutant (oda9) had a
mutation in the IC78 (intermediate chain 78) gene, resulting in a flagellar ODA defect. The
human ortholog of IC78 (DNAI1) was cloned and tested in 6 unrelated PCD patients with
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ODA defects and biallelic mutations were identified in one PCD patient.33 Two studies
reported biallelic mutations in three additional unrelated patients with PCD.44,45
Subsequently, a large study comprising of 179 unrelated patients revealed 9% (14 with
biallelic and 2 with only monoallelic mutations) of all PCD patients carry mutations in
DNAI1.46 Thus, taken together from all published literature, mutations in DNAI1 were seen
in approximately 10% (22 of 226) of all PCD patients and it increased to 14%, if only
patients with ODA defects were considered.33,44-46 Despite allelic heterogeneity, the
IVS1+2_3insT founder mutation represented 55% of all the mutant alleles, as well as
mutation clusters were seen in other exons (exons 13, 16, and 17), and these observations
became the basis for the clinical molecular genetic test for PCD.33,44-47 In addition,
IVS1+2_3insT founder mutation appears to be more common in individuals of the
Caucasian descent.46 A recent study from Europe in 104 PCD patients (without phenotypic
preselection) revealed biallelic mutations in DNAI1 in only 2% of the patients.48
Interestingly, these authors also observed 3 unrelated PCD patients harboring the
IVS1+2_3insT founder mutation in DNAI1.
DNAH5—The DNAH5 (dynein axonemal heavy chain 5) (MIM#603335) gene was
identified as a causative gene for PCD using homozygosity mapping. This approach requires
the analysis of a large affected inbred family and assumes that the recessive disorder is
caused by a homozygous mutation that is inherited from the common ancestor. Using a large
Arab inbred family with PCD, Omran and colleagues found the locus on chromosome 5,
which included DNAH5 within the shared interval.49DNAH5 was a candidate gene for PCD
because the mutation in its ortholog γ-HC (gamma-heavy chain) in Chlamydomonas caused
flagellar immotility and ODA defects; and indeed, mutations were observed in 8 unrelated
PCD families.36 Subsequently, the same group carried out large scale studies using 134
unrelated PCD patients and found that ~28% of all PCD patients harbor mutations in
DNAH5.50,51 Despite allelic heterogeneity, mutation clusters were observed in five exons
(exons 34, 50, 63, 76 and 77), which assisted in the development of the first clinical
molecular genetic test for PCD.47 Immunofluorescence studies on the respiratory epithelium
and sperm flagella of patients known to harbor biallelic DNAH5 mutations showed that the
mutant protein is present in the microtubule organizing center (MTOC) of the respiratory
epithelial cells, but failed to localize along the axonemal shaft.28,52 Interestingly, sperm
analysis from a male patient showed normal immunofluoresence staining pattern; thus,
DNAH5 is not mislocalized in the sperm flagella.52
DNAI2—The DNAI2 (dynein axonemal intermediate chain 2) (MIM#605483) is an
intermediate chain dynein of the ODA that was cloned and characterized utilizing the
candidate gene approach. Mutations in the Chlamydomonas ortholog (IC69) caused an
immotile mutant strain (oda6) which had loss of ODA.34 Initial studies showed no disease
causing mutations in 16 PCD families, including 6 families with microsatellite marker
alleles concordant for loci on chromosome 17q23-ter (locus for DNAI2).34,53 Very recently,
Loges et al35 used homozygosity mapping and identified linkage to the DNAI2 locus in a
consanguineous Iranian Jewish family, and a homozygous splice mutation (IVS11+1G>C)
in all the affected individuals. Subsequently, they sequenced an additional 105 unrelated
patients (48 with ODA defects) and identified a homozygous splice mutation (IVS3-3T>G)
in a Hungarian PCD family and a homozygous stop mutation (R263X) in a German patient.
Thus, DNAI2 mutations are found in ~ 2% of all PCD families and 4% of PCD families
with documented ODA defects.35
DNAH11—Genetics of DNAH11 (dynein axonemal heavy chain 11) (MIM#603339) are
still emerging. A patient with uniparental isodisomy of chromosome 7 presented with cystic
fibrosis due to the common homozygous mutation (deltaF508) in CFTR (MIM# 602421). In
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addition, this patient had situs inversus, which is not part of the spectrum of cystic fibrosis.30
Upon investigation of the region near CFTR on chromosome 7, DNAH11 emerged as a
candidate gene because mutations in the ortholog β-HC (beta-heavy chain) dynein and left
right dynein (lrd) caused motility defects in Chlamydomonas oda4 mutant strain (reviewed
in reference22) and situs inversus in mice54,55 respectively. Sequencing of DNAH11 in this
cystic fibrosis patient with situs inversus revealed a homozygous nonsense mutation
(R2852X).30 Because this patient had airways disease due to cystic fibrosis and no defined
ciliary ultrastructural defect, it was not certain if the patient also had PCD, or only isolated
situs inversus; hence, the status of DNAH11 as a PCD causing gene remained undefined.
Very recently, a large German family with 5 affected individuals (and Kartagener syndrome)
was found to harbor biallelic compound heterozygous truncating mutations in DNAH11.37
Although, the electron microscopic analysis and immunofluorescence localization in these
patients showed normal dynein arms, they had abnormal ciliary beat patterns. Since PCD
patients with normal dynein arms are difficult to diagnose, it will be important to carry out
large scale genetic studies of DNAH11 in PCD subjects to decipher if DNAH11 plays an
important role in PCD patients with normal DA.
TXNDC3—Thioredoxin-nucleoside diphosphate (TXNDC3) (MIM#607421) ortholog in
Chlamydomonas (LC3 (Light chain 3) and LC5 (light chain 5)) and sea urchin ((IC1
(intermediate chain 1)) is a component of sperm ODA. Due to the involvement of TXNDC3
in the ODA, it was considered a candidate gene and tested in 41 unrelated PCD patients.31
Only one patient harbored a nonsense mutation (L426X) on one allele inherited from the
mother31 and a common intronic variant (c.271-27C>T) on the trans allele. Although this
variant is present in 1% of non-PCD control subjects, it occurs near the branch point in the
intron that is involved in the splicing. TXNDC3 encodes two transcripts, one full length
isoform and a novel short isoform TXNDC3d7 (inframe deletion of exon 7) that is thought
to bind microtubules. The authors concluded that the variant was pathogenic in the patient
with a nonsense mutation on one allele and the variant on the other allele because the levels
of the short isoform (TXNDC3d7) were reduced in this PCD patient thereby affecting the
ratio of the two isoforms.31
KTU—A truncating homozygous mutation in Ktu (previously known as Kintoun or knt)
(MIM#612517) in Medaka fish causes laterality defects, polycystic kidney disease and
impaired sperm motility in male fish. Ultrastructural analysis of the cilia of Kupffer’s
vesicle (functionally equivalent to the mouse node) and flagella of sperm from the fish
revealed ODA+IDA defects.32 Similar ultrastructural defects were found in the paralyzed
flagella mutant strain of Chlamydomonas (pf13) that harbored mutation in the PF13 gene
(ortholog of KTU), required for the ODA assembly.32KTU does not belong to the dynein
family genes, but it is a cytoplasmic protein that is required for the assembly of the dynein
complex and hence was considered a candidate gene for PCD.32 A total of 112 unrelated
PCD patients were tested for the mutations in KTU and two unrelated inbred families were
found to harbor truncating mutations; the ciliary ultrastructural analysis revealed ODA+IDA
defects. Of the 112 PCD families tested, only 17 had defined ODA+IDA defects; thus,
mutations in KTU occur in 12% PCD patients with ODA+IDA defects.32 Interestingly, KTU
mutations caused PCD in humans, but polycystic kidney disease in fish, perhaps due to the
difference in the origin of the kidneys that are mesonephric in fish and metanephric in
mammals.
RSPH9—Very recently, Castleman et al56 identified the mutations in RSPH9 (radial spoke
head protein 9). The authors carried out homozygosity mapping and identified the disease
interval on chromosome 6 and subsequently discovered the inframe deletion (K268del) in
RSPH9 in two Arab Bedouin families. The ultrastructural analysis from the patients who
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harbored mutations was the mixture of 9+2 or 9+0 microtubular configuration in one family
and the normal dynein arms in the other family.56 Interestingly, Chlamydomonas motility
defective mutant; pf17 that harbors mutation in the orthologous gene RSP9, shows the
absence of entire radial spoke head and the central pair displacement.57
RSPH4A—Another PCD causing gene that has emerged very recently is RSPH4A (radial
spoke head protein 4A).56 This gene was identified by the virtue of homozygosity mapping
in three inbred Pakistani families. Homozygous nonsense mutation (Q154X) was identified
in all three inbred and one out-bred Pakistani families in RSPH4A. In addition, one family
of a Caucasian descent was compound heterozygous for the mutations (Q109X + R490X) in
this gene. Ultrastructural analysis in all of the five PCD families with the mutation showed
transposition defects with the absence of central pair and 9+0 or 8+1 microtubule
configurations.56RSPH4A is orthologous to the Chlamydomonas RSP4 and RSP6. However,
Chlamydomonas motility defective mutants pf1 and pf26 lacking RSP4 or RSP6
respectively, show absence of radial spoke head.58
Genes tested and found to be negative in PCD
A number of other PCD candidate genes have been tested and found to be negative in PCD
patients. These genes include DNAH9 (dynein axonemal heavy chain 9), DNAH17 (dynein
axonemal heavy chain 17), DNAL1 (dynein axonemal light chain 1), DNAL4 (dynein
axonemal light chain 4), TCTE3 (T complex-associated testis-expressed 3), DYNLL2
(dynein light chain 2), DNALI1 (dynein axonemal light intermediate polypeptide 1 (HP28)),
DNAH3 (dynein axonemal heavy chain 3), DNAH7 (dynein axonemal heavy chain 7),
SPAG6 (sperm-associated antigen 6), SPAG16 (sperm-associated antigen 16), DPCD
(deleted in PCD), and FOXJ1 (forkhead box J1 (HFH-4)). The details about the number of
patients tested for each of these genes is given in Table 2. Some of these genes may still be
candidates for PCD as they were either tested in a small cohort of patients or the patients
were not preselected based on ultrastructural findings to test for the appropriate axonemal
component gene.
PCD co-segregating with other syndromes (OFD1 and RPGR)
In a few instances, PCD cosegregates with other genetic conditions and the causative genes
primarily do not affect ciliary motor function. A large inbred Polish kindred was identified
with a novel X-linked mental retardation syndrome, together with the compatible clinical
PCD phenotype and dyskinetic cilia. Linkage studies followed by comparative genomic
analysis identified the locus on the X chromosome including OFD1 (formerly known as
CXORF5) (MIM# 311200). Mutation analysis confirmed the frameshift mutation in OFD1
in all the affected individuals tested from the Polish family.59 OFD1 is localized to the
centrosomes and the basal body of the primary cilia and does not affect ciliary motor
function.60,61 The index patient with the OFD1 mutation had disorganized ciliary beat
suggesting the role of OFD1 in the respiratory epithelial ciliary function.59
A family consisting of two probands has been described by Moore et al.,62 with the X-linked
retinitis pigmentosa (xlRP) (MIM# 268000), oto-sino-pulmonary symptoms consistent with
PCD, and multiple abnormalities of all the ciliary components by ultrastructural analysis.
Upon sequencing, both patients harbored a 57 bp deletion that is predicted to cause a
truncated protein in RPGR that resides on the X chromosome (MIM# 312610).62
Furthermore, Zito et al.,63 described a patient with PCD and mild hearing loss together with
xlRP. They detected a frameshift mutation in RPGR. In addition, Iannaccone et al.64 report a
family with PCD and otitis media with bronchitis together with xlRP and the presence of a
missense mutation in RPGR. RPGR protein is expressed in rods and cones and is essential
for photoreceptor maintenance and viability.65 RPGR is also expressed in cochlear,
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bronchial and sinus epithelial lining cells,64,66 indicating a possible functional role for the
broad phenotype in patients with RPGR mutations.
Animal models for PCD
Animal models for PCD are available that are either naturally occurring or constructed via
genetic manipulations. They include dogs,67-71 cats,72 pigs,73 rats74 and mice. Causative
genes in the animal models other than the mouse models are not yet known. Several
axonemal component gene knock-out mice have been created including Mdnah5 (mouse
dnah5),75,76lrd,54,55,77-79Dpcd/poll (deleted in PCD/polymerase lambda),80Pcdp1 (PCD
protein 1),81hydin,82-85Tektin-t,86Mdhc7 (mouse dynein heavy chain 7, human ortholog
(DNAH1; dynein axonemal heavy chain 1)),87,88Foxj1/Hfh4,89Spag16,90-92Spag6,90,93 and
Spag16/Spag6 double knock-outs.94 None of these mice models presented with the classic
PCD phenotype, except for the Mdnah5 and Dpcd/poll. None of these genes harbored
mutations in the human orthologs (see Tables 1 and 2) in the PCD patients, except for the
Mdnah5 and lrd (discussed in detail, below).
Mdnah5 deficient mouse
Mdnah5 nullizygous mice were generated by transgenic insertional mutagenesis that led to a
frameshift mutation. These mice presented with the classical features of PCD, including
respiratory infections, situs abnormalities, immotility of the cilia and ultrastructural analysis
revealing absent ODA.75 Consistent with the autosomal recessive mode of inheritance, only
homozygous mutant mice presented with the PCD phenotype. Almost all homozygous
mutant mice developed hydrocephalus leading to perinatal lethality and indeed partial ODA
defects were noted in the ependymal cells that are lining the brain ventricles and the
aqueduct.95 Recently, another group identified the homozygous mice with an inframe
deletion of 593 amino acids (exons 7-17) during the ENU (ethylnitrosourea) mutagenesis
screen.76 These mice, (known as Dnahc5del593), presented with dyskinetic cilia and ODA
defects in respiratory cilia. Mice presented with situs inversus totalis (35%) and heterotaxy
(40%) with congenital heart defects leading to post-natal lethality. DNAH5 is the only gene
thus far known to cause PCD in humans and mice.36,51
Other interesting mouse models
Another mouse model with the classic PCD phenotype is Dpcd/poll knock out mice
presenting with sinusitis, situs inversus, hydrocephalus, male infertility and ciliary IDA
defect.80 The initial study considered the mouse phenotype to be caused by the homozygous
deletion of poll,80 but later it was discovered that another gene known as Dpcd was also
deleted in these mice.96 In addition, mice generated with the catalytic domain of poll did not
have a PCD phenotype.97 Thus; taken together, it appears that poll is not a candidate for the
PCD phenotype in these mice that may be due to the Dpcd deletion. The human ortholog
(DPCD) was tested in 51 patients with PCD (15 with IDA defects) and no mutations were
discovered.96 A note-worthy model is for the left-right-dynein (lrd) deficient mice (lrd mice,
iv mice and lgl mice) where classic PCD phenotype is not observed, but these mice present
with the situs abnormalities and normal dynein arms by ultrastructural analysis.54,55,77-79




Ciliated cells line the airways of the nasopharynx, middle ear, paranasal sinuses, and lower
respiratory tract from the trachea to the terminal airways.98 Each ciliated cell has
approximately 200 cilia projecting from its surface in the same orientation. Coordinated
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movement of the cilia sweeps the periciliary fluid and overlying mucus, resulting in vectoral
movement of mucus out of the lower respiratory tract. The mucociliary escalator is the
primary defense mechanism of the airways,99,100 and any functional disruption, primary or
acquired, can lead to chronic sino-pulmonary symptoms.
Early clinical manifestations
The clinical features of PCD manifest early in life (Table 3). Most PCD patients (70-80%)
present in the neonatal period with respiratory distress, which suggests that motile cilia are
critical for effective clearance of fetal lung fluid.9,101-103 Several case reports have
emphasized unexplained atelectasis or pneumonia in term newborns, which can present with
hypoxemia or even acute respiratory failure requiring mechanical ventilation. Despite this
early clinical feature, the association of newborn respiratory distress with PCD has been
under-recognized and diagnosis is often delayed. In a retrospective review, investigators
have found the mean age of PCD diagnosis was more than 4 years of age despite these early
pulmonary manifestations.104 Persistent rhinitis and chronic cough are present since early
infancy. Chronic cough is consistently reported in the majority of subjects (84-100%), and
typically characterized as wet and productive.9,105,106 The infant may also exhibit poor
feeding and failure to thrive in the early years of life,107 similar to cystic fibrosis, thus,
making the diagnosis a challenge.
Laterality defects
A classic phenotypic feature of PCD that may be detected at birth are left-right laterality
defects. The prevalence of situs inversus totalis tends to be over 60% in the pediatric
population, as opposed to 50% in the adult population, suggesting that situs abnormalities
may serve as a marker to aid in disease diagnosis.9,105,106,108,109 Without functional nodal
cilia in the embryonic period, thoracoabdominal orientation is random and not genetically
pre-programmed.
Heterotaxy and congenital cardiovascular defects
Patients with Kartagener syndrome have a greater incidence of congenital cardiovascular
defects, and recent studies have found that approximately 6% of PCD patients have
heterotaxy (situs ambiguus or organ laterality defects other than situs inversus totalis),110
which is associated with increased morbidity due to complex cardiovascular anomalies.
Heterotaxia syndromes include abdominal situs inversus, polysplenia (left isomerism) and
asplenia (right isomerism and Ivemark) syndromes.111 It is therefore recommended that
patients with anomalies consistent with situs ambiguuus or heterotaxy, including congenital
heart disease, with neonatal respiratory distress or chronic respiratory tract infections be
referred for PCD screening.
Upper respiratory tract
The upper respiratory tract is frequently involved in PCD. Rhinosinusitis (100%) and otitis
media (95%) are cardinal features of the disease, are responsible for much of the morbidity
associated with PCD in early childhood.9,104 Nasal congestion and/or rhinorrhea are very
common, and some patients have nasal polyposis. Middle ear disease is described in
virtually all cases of PCD with varying degrees of chronic otitis media and persistent middle
ear effusions, such that patients are often first referred to an otolaryngologist, who must
have a high index of suspicion for the disease. The middle ear disease often leads to multiple
sets of pressure-equalization (PE) tubes in early childhood,9,105,112 which can be
complicated by persistent, purulent otorrhea. Middle ear disease often leads to conductive
hearing loss.
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Most patients (and their family members) report a chronic, productive cough as a prominent
symptom of PCD, since cough compensates for the lack of effective mucociliary clearance.
Physiologic data have shown that “effective” coughs can produce effective lung clearance,
almost equal to normal mucociliary clearance over short time periods, even in PCD subjects
with severe ciliary defects.113 Impaired mucociliary clearance of the lower respiratory tract
leads to recurrent episodes of pneumonia or bronchitis. Bacterial cultures of lower
respiratory secretions most commonly yield non-typeable Haemophilus influenzae,
Staphylococcus aureus, and Streptococcus pneumoniae. Pseudomonas aeruginosa infection,
including mucoid strains, has also been reported, most often in older individuals.9
Bronchiectasis; severity of disease
Clinical and radiographic evidence of bronchiectasis develops as the disease progresses,
often accompanied by digital clubbing. Review of high-resolution computerized tomography
(CT) findings of the lungs showed that bronchiectasis primarily involves the middle and
lower lobes (100% adults and 55% pediatric patients).114,115 Bronchiectasis and obstructive
impairment may be apparent in preschool children.106,116 When compared to cystic fibrosis
(CF), pulmonary involvement is generally milder in PCD when controlled for age and
gender. Studies examining lung function decline suggest that forced expiratory volume in
one second (FEV1) in a cross-section of PCD patients decreases slower than that seen in
CF.9,117 PCD patients can develop chronic respiratory impairment (25% in one series) as
defined by hypoxemia or an FEV1 less than 40% predicted for age and some may eventually
require lung transplantation.9,118 Pulmonary involvement also adversely impacts quality of
life as PCD patients mature, and is increasingly recognized as both medical and public
understanding in ciliopathies increase.119
Infertility
Men with PCD are typically infertile as a result of impaired spermatozoa motility secondary
to defective sperm flagella, although it is not a universal finding.120,121 Males with PCD
may occasionally have intact spermatozoa motility, suggesting sperm tails may retain some
function or could have different genetic control than cilia.120 Female fertility is more
variable; with reduced fertility in some that report delay in conception following unprotected
intercourse, presumably due to abnormal ciliary function in the Fallopian tube.120,122
Other clinical manifestations
Other clinical manifestations of PCD are rare and less well understood. Several reports have
linked hydrocephalus with PCD, hypothetically due to impaired cerebrospinal fluid flow
secondary to dysfunctional motile cilia that line the ventricular ependymal cells.123,124
Hydrocephalus is frequently found in murine PCD models, but its incidence or clinical
relevance in PCD patients is unclear. Retinitis pigmentosa has recently been linked to some
forms of PCD,62-64,125 and recently, bronchiectasis was reported in 37% of patients who
have autosomal-dominant polycystic kidney disease.126 Findings in these studies suggest
phenotypic overlap between sensory and motile ciliopathies.
DIFFERENTIAL DIAGNOSIS
The diagnosis of primary ciliary dyskinesia is often delayed until late childhood or
adulthood as a consequence of the heterogeneous nature of the disease, lack of physician
knowledge of disease characteristics and the technical expertise required for an accurate
diagnosis.9,104 Several clinical presentations warrant consideration of PCD in the
differential diagnosis, including infants with unexplained respiratory distress and/or
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laterality defect, and infants and children who present with chronic cough, nasal drainage
and sino-pulmonary disease.
(a) Neonatal respiratory distress
The differential diagnosis for neonatal respiratory distress in a term infant is extensive, and
includes transient tachypnea of the newborn (TTNB), neonatal pneumonia and meconium
aspiration,127 as well as rarer causes such as surfactant protein deficiency128 and interstitial
lung disease. Infants with PCD are often misdiagnosed with TTNB or neonatal pneumonia
in the newborn period. Surfactant protein deficiency, a rare form of interstitial lung disease
(see below), presents in infancy with severe tachypnea and hypoxia, often requiring
mechanical ventilation. These children typically have diffuse interstitial disease on chest CT
and alveolar proteinosis on bronchoalveolar lavage, neither of which are seen in PCD.129,130
(b) Laterality defects
Situs inversus totalis occurs in approximately 50% of patients with PCD;9,131 approximately
25% of subjects with situs inversus have PCD.132 Other situs anomalies (heterotaxy), such
as abdominal situs inversus, polysplenia, and right and left isomerism, may also be found in
PCD;110,133 and, in conjunction with neonatal respiratory distress, should prompt an
evaluation for PCD. Congenital heart disease, especially involving defects of laterality, may
also be present in subjects with PCD;110,131,133 however, respiratory distress secondary to
PCD may be difficult to distinguish from distress secondary to cardiac defects, thereby,
delaying diagnosis.
(c) Chronic cough, nasal congestion and sino-pulmonary disease
The differential diagnosis includes CF, asthma, allergic rhinitis, gastroesophageal reflux
disease (with or without aspiration), immunodeficiency, interstitial lung disease, and
idiopathic bronchiectasis (see Table 4).9,131,134
Cystic Fibrosis
Both PCD and CF are characterized by chronic, productive cough, obstructive impairment
on lung function testing,116,135-137 and radiologic changes including hyperinflation,
subsegmental atelectasis, and bronchiectasis.9,134,135,138 Parents of PCD children often note
that cough was present from birth, which may distinguish these patients from those with
CF.9,134 Digital clubbing, chronic sinusitis and nasal polyps can occur in both
diseases.9,131,134 The gastrointestinal and nutritional issues commonly seen in CF (e.g.
failure to thrive, steatorrhea, and liver disease) are not typical of PCD.134,138 In contrast,
chronic otitis media is a hallmark of PCD, occurring in 90-100% of PCD patients, while the
incidence of otitis media in CF is not increased compared to the general population.9,131 CF
can be ruled out by pilocarpine sweat electrolyte testing and/or by CFTR gene mutation
analysis.139
Asthma and Allergic Rhinitis
PCD and asthma can both be characterized by chronic cough; however, this cough is usually
dry and non-productive in asthma as opposed to the wet cough of PCD.140-142 Atelectasis is
a common finding in both PCD and asthma, often associated with hyperinflation.143,144
Obstructive impairment on pulmonary function testing is seen in both PCD and asthma;
however, bronchodilator responsiveness, a common feature in asthma, is not typical in
children with PCD.131,141
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Gastroesophageal reflux disease and aspiration
Gastroesphageal reflux disease (GERD) may present with a variety of pulmonary and upper
respiratory tract symptoms, including cough, wheeze, rhinorrhea, sneezing, and recurrent
pneumonia.145,146 Aspiration pneumonia (chemical pneumonitis) can occur as a result of
GERD typically involves upper lobes on chest radiograph,147 while radiologic findings in
PCD have a predilection for the right middle lobe and lingula.134
Immunodeficiency
Primary immunodeficiencies often present with chronic sino-pulmonary infections, resulting
in a distinct overlap in symptoms with PCD.148,149 The antibody deficiencies seen with
humoral diseases result in increased susceptibility to encapsulated bacteria (Staphylococcus
aureus, Streptococcus pneumoniae, and Haemophilus influenzae), and lead to recurrent
pneumonia, sinus infection, and otitis media with symptoms which overlap with PCD.
Interstitial Lung Disease
Interstitial lung disease (ILD) is a descriptive term that encompasses a spectrum of over 100
lung diseases of both known and unknown etiology, all of which involve damage of the
alveolar wall, accumulation of extracellular matrix within the pulmonary interstitium, and
destruction of normal alveolar-capillary complexes, with progression towards pulmonary
fibrosis.130,150 Patients with ILD may present in infancy or childhood with pulmonary
infiltrates, hypoxia, cough, tachypnea, and frequent infections.129,130,150 Pulmonary
function testing in ILD typically shows restrictive impairment129 that is distinct from the
obstructive impairment seen in PCD. Typical findings on high-resolution chest CT (HRCT)
in ILD include ground-glass opacities, septal thickening, geographic hyperlucency,
consolidation, and cysts or nodules,129 all of which are distinct from the hyperinflation,
atelectasis, infiltrates, bronchial thickening, and bronchiectasis seen in PCD.9,105
DIAGNOSTIC APPROACH
The diagnostic approach to PCD is evolving. Until recently, the only definitive diagnostic
test had been electron microscopy to define ultrastructural defects in cilia supported by light
microscopic analysis demonstrating obvious ciliary dysfunction (immotile or profoundly
dyskinetic cilia). Emerging diagnostic tests include genetic testing, nasal nitric oxide
measurement, immunofluorescent analysis, and high-speed videomicroscopy to define
subtle ciliary dysmotility. At this point, these specialized diagnostic tests are not
standardized or readily available; therefore, referral to research centers may be needed. A
systematic research approach to diagnosing PCD has defined some individuals with normal
ciliary ultrastructure, who have PCD based on identification of disease-causing mutations in
a ciliary genes associated with subtle defects in ciliary motility (as described above). It is
conceivable that ultrastructural defects may represent a small fraction of individuals with a
genetic defect of cilia in PCD.
DIAGNOSTIC TESTS
Ultrastructural changes in PCD
Ultrastructural defects of cilia associated with mucociliary dysfunction was first described in
1975 by Afzelius et al.4,151 These reports identified absent and dysmorphic dynein arms in
spermatozoa and airway cilia of affected individuals and subsequent reports have supported
these observations. Current ciliary ultrastructural diagnostic criteria include absence or
structural modification of either inner or outer dynein arms individually, or of both dynein
arms152-155 (Fig. 3). Cilia with defective radial spokes and transposition of a peripheral pair
of microtubules to occupy the central axis also have been associated with disease consistent
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with PCD, although such cases appear to be rare.156,157 Although a variety of other ciliary
ultrastructural defects such as axonemal changes, are reported in respiratory disease, these
changes are “secondary” and can be traced to infection, inflammation, or irritant
exposure.158,159 These abnormalities are distinguished from the index ultrastructural lesions
of PCD by their lack of universality in all cilia of affected individuals. Indeed, studies of
healthy airways have demonstrated a background of 3-5% defective cilia even in airways of
healthy individuals.160 Ultrastructural analysis is cumbersome requiring technical expertise,
sophisticated electron optical imaging, and is only available at a limited number of centers.
While ultrastructural analysis has proved invaluable in the diagnosis of PCD and has been
considered the “gold standard”, new studies37 are emerging to demonstrate that affected
individuals can exhibit the clinical phenotype of PCD, and mutations in ciliary genes, but
have normal ciliary ultrastructure. This observation points to the broadening definition of
PCD which is being brought about by advances in molecular genetics. These molecular
studies are important, as they support a growing awareness among researchers that PCD is
an underreported syndrome perhaps, in part, because of the limitation of ciliary
ultrastructural analysis.161
Ciliary motility abnormalities in PCD
The first reports by Afzelius et al.4,151 indicated spermatozoa and airway cilia from the
affected individuals were totally immotile, which led to the early descriptive name,
“immotile cilia syndrome”. Subsequent studies among other affected individuals reported
motile, but dyskinetic, ciliary activity, which led to adoption of “primary ciliary dyskinesia
(PCD)”. PCD more correctly described the typical pattern of motility, and implied
heterogeneous genetic basis of the syndrome. Motile, but dyskinetic, cilia usually beat out of
synchrony relative to neighboring cilia. Typically, dyskinesia is accompanied by markedly
attenuated ciliary beat frequency (<3 Hz at 22°C) although cases of vigorous motility have
been documented. Ongoing research is studying relationships between ciliary kinetics and
beat frequency, specific ultrastructural characteristics, and specific dynein mutations
conferring PCD.
Nasal Nitric Oxide testing
Nasal nitric oxide (NO) measurements is emerging as a non-invasive screening test for PCD,
based on multiple studies demonstrating that nasal NO production is markedly reduced
(5-20% of normal) in patients with PCD.7-10,162 The exact mechanism for reduced nasal NO
in PCD has yet to be elucidated, and the biologic function of nasal NO has not been fully
defined. Postulated functions include regulation of ciliary motility163 and antimicrobial
activity.164 Nasal NO, produced predominantly in the paranasal sinuses, is much more
abundant (10 – 50 fold greater) than in the lower airways.10,162,165 Consequently, accurate
measurement of nasal NO production requires specific techniques for palate closure, in order
to ensure that there is no dilution of the nasal NO by air from the lower airways.134,165
While nasal NO is extremely low in patients with PCD, it is also reduced (though not as
low) in patients with cystic fibrosis.134,165 Sinus disease (acute or chronic) may result in
falsely diminished nasal NO levels in otherwise healthy subjects.165 Because no FDA-
approved devices for measurement of nasal NO are available, nasal NO measurement is
used predominantly in research studies in the United States, but has become part of the
diagnostic clinical testing at centers in Europe.166 Normal values are published for children
as young as six years of age.167 Recent studies have focused on standardizing techniques for
measuring nasal NO especially in children under 6 years of age who are unable to cooperate
with maneuvers to close the soft palate.168,169
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Immunofluorescent analysis for ciliary proteins holds diagnostic potential for PCD. Recent
studies showed that PCD patients with ODA defects had absence of DNAH5 staining from
the entire axoneme or from the distal portion and accumulation of DNAH5 at the
microtubule-organizing center, in contrast to all control individuals, including disease
controls (recurrent respiratory infections unrelated to PCD) who had normal DNAH5
staining along the ciliary axoneme.52,170 This method is performed on nasal epithelial cells
obtained via non-invasive trans-nasal brushing. The main advantage of this method is that it
can detect the changes along the entire length of the ciliary axoneme. At present
immunofluorescent staining is available at one research laboratory in Germany with limited
supply of ciliary protein specific antibodies.
Genetic testing
The diagnosis of PCD is challenging due to the requirement of cumbersome ultrastructural
or immunofluorescent analyses, and only a few laboratories can offer those tests. Defining
biallelic mutations in trans (inheriting a mutation from each parent) in a PCD patient in the
causative gene would confirm the diagnosis. But, genetic diagnosis for PCD is also
challenging due to the genetic heterogeneity and the large size of PCD-causing genes. In
addition, despite the identification of several of PCD causing genes, the number of PCD
patients harboring mutations in some of these genes is small and thus, limits the
development of a robust clinical genetic test. DNAI1 and DNAH5 appear to be major
causative genes in almost 30-38% of all PCD families.33,36,44-46,48,51 Since mutations in
these genes have been exclusively identified in patients with ODA defects, the mutation
detection rate is higher (~50-60%) in PCD patients with ODA defects. Despite allelic
heterogeneity in DNAI1 and DNAH5, mutation clusters were observed in 9 exons of DNAI1
(exons 1, 13, 16, and 17) and DNAH5 (exons 34, 50, 63, 76 and 77). Based on published
reports, we estimate that analysis of the 9 exons would lead to the identification of at least
one mutant allele in approximately 24% of all PCD patients. The DNA from these patients
can then be sequenced to test for the second mutation. The first PCD clinical genetic assay
was developed that required sequencing of only 9 exons (out of 100 exons),28,47 and a
commercial laboratory subsequently developed a genetic assay that tests for the known 60
mutant alleles of DNAI1 and DNAH5. For the full listing of the laboratories offering PCD
genetic tests please check (url: http://www.genetests.org/). Sequence based assays are
expensive; hence, alternative approaches, are being considered such as melting curve
analysis and microarray chips. The benefit of these alternative methods is the ease of
addition of the new genetic mutations as they are discovered, which can assist in further
increase in specificity of the genetic test.
MANAGEMENT
Medical management of lung disease
Currently, there are no therapies that have been adequately studied to definitively prove their
efficacy in the treatment of PCD. Treatments that are used in clinical practice tend to be
extrapolated from CF clinical trials. There is evidence, however, from the observational data
of clinical case series, that early diagnosis and management of patients with PCD in a
specialized PCD clinic may improve long term lung function outcomes.171 The disease
management approach reported by Ellerman and Bisgaard171 followed an algorithm very
similar to the CF disease management approach. A number of high quality randomized
controlled trials of therapy have been published to help establish an evidence based
approach to care of CF.172 CF medical management practices which have some biological
rationale for extrapolation to PCD, include daily airway clearance, judicious use of
antibiotics, infection control and attention to nutritional status. Generally antibiotics are used
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acutely with disease exacerbation and are prescribed according to bacteria grown in the last
sputum culture. Chronic suppressive use of antibiotics would be considered, if a patient is
repeatedly growing Pseudomonas aeruginosa in the sputum. There are no data to
recommend for or against agents that improve mucociliary clearance or inflammation in
PCD. Clinical utility of bronchodilators has not been demonstrated in PCD. Monitoring for
progression of lung disease should be an important part of the regular clinic visit. At present,
there are no clinical practice guidelines to direct frequency of clinic visits or additional
testing. Based on the PCD management approach reported by Ellerman and Bisgaard 171 and
clinical practices used for cystic fibrosis, tests to consider include lung function testing and
respiratory cultures every 3-6 months and lung imaging on an annual or biannual basis.
Consideration should be given for obtaining a chest CT, instead of a plain chest radiograph,
at the time of diagnosis or at intervals during follow-up, since chest CT is the gold standard
for diagnosing bronchiectasis.173 The additional radiation of a chest CT must be weighed
against the potential “benefit” of early recognition of bronchiectasis.
Surgical management of lung disease
Lobectomy is generally not recommended since PCD is a generalized airway disease.
However, lobectomy has been shown to improve symptoms and to have low perioperative
mortality in case series of selected patients with PCD174 and idiopathic bronchiectasis.175
Consideration for lobectomy should be limited to selected patients with severe localized
bronchiectasis with frequent febrile episodes or, severe hemoptysis and failure of
conservative medical management with antibiotics, airway clearance and embolotherapy.174
Surgery should only be performed in centers with specialized expertise. Lung
transplantation is an option once a patient has reached end-stage lung disease. There are at
least 9 reported cases of successful lung transplantation in patients with PCD.176 There are
no longitudinal survival data published in order to develop criteria for referral for lung
transplantation in PCD.
Management of chronic otitis media
The management of serous otitis and recurrent otitis media in PCD is controversial. While
some otolaryngologists argue that myringotomy tubes can be harmful and should be
avoided, others argue that myringotomy tubes allow hearing and speech to develop in the
infant or toddler with hearing loss due to chronic serous otitis. The proponents against tubes
suggest that they cause annoying chronic mucopurulent drainage of the middle ear, pose a
risk of chronic middle ear perforation and that the natural history of hearing loss is that it
normalizes by age 12 years, making these procedures unnecessary.177 On the other hand,
mucopurulent drainage responds to treatment with local antibiotics and there is no hard data
to show that chronic middle ear perforation is a common complication. In addition, delayed
speech development can have profound effects on language development and subsequent
school performance. Hearing aids may be used instead of myringotomy tubes, however they
are sometimes not well tolerated in the preschool age group.
Specialized PCD diagnostic and treatment centers
A multi-disciplinary “disease management” approach to chronic disease is now well
recognized to be the most successful strategy for improving patient outcomes.178 Key
elements of advancing disease management include research, performance measurement and
quality improvement.179 When one considers that PCD is a chronic airways disease with
many similarities to CF including a similar (albeit slower) progression of lung function
deterioration and lower airways bacterial colonization with age,9 the notion of a need for
specialty “PCD Centers” seems obvious. Improvement in survival and quality of life over
the last 30 years for patients with CF can be largely attributed to the better treatment
developed at major CF centers.180 In addition to improved clinical outcomes, disease-
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specific centers are generally regarded favorably by patients and have numerous
psychosocial benefits, including the opportunity to meet other families/patients with the
same rare disease and share experiences.181 Finally, major CF centers also provide a natural
infrastructure for the conduct of clinical research to further improve outcomes.139 Good
medical management in a specialized PCD diagnostic and treatment center will probably
provide the PCD patient with the best chance for preservation of lung function over time.
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Diversity of ciliary axoneme. Cross section of non motile (9+0 arrangement) and motile cilia
(9+2 and 9+0 arrangement) are shown.27,182 Studies to date have not determined whether
the 9+0 monocilium has radial spokes. The model showing synchronous motion of motile
(9+2), rotatory motion of motile monocilium (9+0) and immotile monocilium (9+0) is also
shown.
* Solitary axoneme in the sperm mirrors the structure of the cilium
§ Subcellular structure of the kinocilum is debatable. Some reports indicate 9+0 while others
indicate 9+2 configuration. The function of the kinocilium is also not clear as it disappears
during the mammalian early postnatal period.183
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Schematic diagram of the eukaryotic cilium. Cross-section illustrates the 9+2 configuration
of nine peripheral microtubular doublets surrounding a central pair microtubule complex.
The expanded view of a microtubular doublet schematically depicts cross-sections of the
tubulin protofilaments including those shared by the A and B tubules. The dynein arms in
the expanded view are rendered to schematically depict several light, intermediate, and
heavy chains comprising each of these structures. While the outer arm exhibits a specific
distribution of dyneins, being uniformly composed of three heavy, two intermediate and at
least 8 light chains, the distribution of dyneins in the inner arm is thought to be more
variable.
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Electron micrographs of nasal cilia from patients with primary ciliary dyskinesia (PCD)
illustrating dynein defects. Far left panel illustrates ultrastructure of a normal cilium from
nasal epithelium of a healthy, clinically unaffected subject. The adjacent panels from three
different PCD patients illustrates defects in both dynein arms, isolated defects of outer
dynein arms only, and isolated defects of inner dynein arms only.
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Table 1














DNAH5 ODA-HC 134 28 10 36,50,51
DNAH11 ODA HC 2 2 0 30,37
DNAI1 ODA IC 226 20 2 33,44-46
104 2 2 48
DNAI2 ODA IC 10 0 0 34
6 0 0 53
106 3 0 35
TXNDC3 ODA LC/IC 41 1 0 31
KTU cytoplasmic* 112 2 0 32
RSPH9 RS 2 2 0 56
RSPH4A RS 5 5 0 56
Abbreviations:
ODA: outer dynein arm, IDA: inner dynein arm, HC: heavy chain, IC: intermediate chain, LC: light chain, RS: radial spoke
*
= cytoplasmic protein requires for the dynein arms assembly
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Table 2














DNAH9 ODA HC 2 0 0 184
DNAH17 ODA HC 4 0 0 185
DNAL1 ODA LC 86 0 0 186
DNAL4 ODA LC 54 0 0 187
TCTE3 ODA LC 36 0 0 188
DYNLL2 ODA LC 58 0 0 53
DNALI1 (HP28) IDA LC 61 0 0 187,189
DNAH3 IDA HC 7 0 0 190
DNAH7 IDA HC 1 0 0 191
DPCD IDA gene 51 0 0 96
SPAG6 CA 54 0 0 185
SPAG16 CA 5 0 0 192
FOXJ1/HFH-4 expressed* 8 0 0 89
Abbreviations:
ODA: outer dynein arm, IDA: inner dynein arm, HC: heavy chain, IC: intermediate chain, LC: light chain, CA: central apparatus
*
= expressed in respiratory cilia
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Table 3
Clinical Features of PCD
Middle ear
 Chronic otitis media
 Conductive hearing loss
Nose and Paranasal sinuses
 Neonatal rhinitis









 Male (and possibly female infertility)
Laterality defects
 Situs inversus totalis
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Table 4
Differential Diagnoses, Presenting Symptoms, and Findings
SYMPTOMS PCD CF Asthma Allergic
Rhinitis
GERD ILD
Cough +++ +++ ++ ++ ++ ++
 frequency chronic, daily chronic intermittent intermittent intermittent intermittent
 character wet wet dry dry or wet dry or wet dry or wet
 time of year year-round year-round often seasonal often
seasonal
year-round year-round
Nasal congestion +++ ++ w/ allergic ++ − −
 frequency chronic, daily intermittent rhinitis intermittent
 time of year year-round year-round often
seasonal
Otitis media +++ − − − + ++
Sinus disease +++ +++ − ++ − −





































obstructive normal normal restrictive
DEFINITIONS:
+++ Occurs in over 75% of patients with classic disease
++ Occurs in many patients with classic disease
+ Occurs in some patients with classic disease
− Occurs at same frequency as in general population
Abbreviations:
PCD: primary ciliary dyskinesia, CF: cystic fibrosis, GERD: gastroesophageal reflux disease, ILD: interstitial lung disease (examples of ILD
presenting in neonatal period include surfactant protein C deficiency and neuroendocrine cell hyperplasia)
Genet Med. Author manuscript; available in PMC 2013 August 09.
